Hereditary leiomyomatosis and renal cell carcinoma pathway (Homo sapiens)

From WikiPathways

Jump to: navigation, search
1-3MitochondrionEpithelial cell or proximal renal tubulePDHA1GlycolysisironTP53pyruvatePRKAB1phospholipidsNFE2L2LDHACO2lactateIronPDK1O2+FHEGLN1glucoseATPNRF2/ARE PathwayPRKAA1PRKAG1glucoseSLC11A2RPS6ACACAACACBpyruvatePRKAB1PRKAA1PRKAG1Acetyl-CoAPDHA2PDHBfatty acidsmalonyl-CoAcitrateAcetyl-CoAL-malateOxaloacetatecitrateNFE2L2KEAP1SSKEAP1CUL3HIF1AGLUT1isocitratealpha-ketoglutarateSuccinyl-CoAsuccinatefumarateL-malateOxaloacetatealpha-ketoglutarateglutamateglutamatealpha-ketoglutaratesuccinateVEGFA


Description

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant hereditary cancer syndrome in which affected individuals are at risk for the development of cutaneous and uterine leiomyomas and kidney cancer. HLRCC is characterized by germline mutation of the tricarboxylic acid cycle (TCA) enzyme, fumarate hydratase (FH). FH-deficient kidney cancer is characterized by impaired oxidative phosphorylation and a metabolic shift to aerobic glycolysis, a form of metabolic reprogramming referred to as the Warburg effect.


AMPK is a negative regulator of the Warburg effect in Fumarate hydratase-deficient kidney cancer. Fumarate hydratase (FH)-deficient kidney cancer, characterized by impaired oxidative phosphorylation, and undergoes a metabolic shift to aerobic glycolysis to generate ATP required for the increased energetic demands of rapidly proliferating cells. The increased glycolysis suppresses expression and activation of AMPK which results in increased S6 and ACC activity, promoting anabolic growth and proliferation. Decreased AMPK results in decreased p53 and the iron transporter, DMT1. The iron responsive proteins, IRP1 and IRP2, as well as the IRP target, transferrin receptor protein 1 (TFRC) are elevated, indicating that cytosolic iron concentrations decrease secondary to decreased DMT1 activity. Prolyl hydroxylase, which is sensitive to iron levels, would be inhibited by decreased cytosolic iron levels, stabilizing HIF1α. Fumarate, which increases in FH- deficient cells, has been shown to inhibit prolyl hydroxylase, which would lead to further stabilization of HIF1α, increasing transcription of factors such as vascular endothelial growth factor (VEGF) and the glucose transporter, GLUT1. Increased fumarate has been shown to succinate KEAP1, thus altering it's conformation and disrupting its ability to induce degradation of Nrf2. Nrf2 transcription is increased activating anti-oxidant response and protecting against oxidative stress. Increased HIF1α would stimulate LDHA, increasing lactate production, and would stimulate PDK1, which inhibits PDH and would decrease entry of pyruvate into the TCA cycle. FH-deficient kidney cancer use a glutamine- dependent reductive carboxylation rather than rather than oxidative metabolism for citrate formation (red arrows). Glutamine is the major source for the increased fatty acid synthesis required for rapid proliferation in these cells with disabled normal oxidative phosphorylation. Potential approaches for treatment of this aggressive form of kidney cancer include agents that stimulate AMPK, agents that target the tumor vasculature and glucose transport, agents that inhibit LDHA and agents that target the critical glutamine-dependent reductive fatty acid/lipid synthetic pathway. (Linehan and Rouault, Clin Cancer Res, 2013)

Quality Tags

Ontology Terms

 

Bibliography

  1. Schmidt L, Linehan W; ''Hereditary leiomyomatosis and renal cell carcinoma''; DovePress, 2014
  2. Linehan WM, Rouault TA; ''Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.''; Clin Cancer Res, 2013 PubMed
  3. Srinivasan R, Ricketts CJ, Sourbier C, Linehan WM; ''New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.''; Clin Cancer Res, 2015 PubMed

History

View all...
CompareRevisionActionTimeUserComment
97123view17:40, 30 April 2018Khansperslabeled cell
97122view17:25, 30 April 2018Khanspersadded lit refs
97007view23:33, 25 April 2018KhanspersModified title
96456view11:46, 15 March 2018EgonwReplaced a secondary ChEBI identifier with a primary identifier.
96443view08:32, 15 March 2018EgonwReplaced secondary ChEBI identifiers with primary identifiers.
95922view18:11, 5 February 2018Khanspersfixed unconnected
95914view16:01, 4 February 2018Khansperscorrected HIF1A interactions
95904view22:03, 2 February 2018Khanspersboard height decrease
95903view22:02, 2 February 2018Khansperstesting a change in board height
95844view21:52, 25 January 2018KhanspersOntology Term : 'renal cell cancer pathway' added !
95843view21:50, 25 January 2018KhanspersOntology Term : 'renal cell carcinoma' added !
95842view21:49, 25 January 2018KhanspersOntology Term : 'leiomyomatosis' added !
95841view21:48, 25 January 2018KhanspersModified description
95840view21:23, 25 January 2018KhanspersNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
ACACAGeneProductENSG00000278540 (Ensembl)
ACACBGeneProductENSG00000076555 (Ensembl)
ATPMetaboliteCHEBI:15422 (ChEBI)
Acetyl-CoAMetaboliteHMDB01206 (HMDB)
CO2MetaboliteCHEBI:16526 (ChEBI)
CUL3GeneProductENSG00000036257 (Ensembl)
EGLN1GeneProductENSG00000135766 (Ensembl)
FHMetaboliteCHEBI:73634 (ChEBI)
GLUT1GeneProductENSG00000117394 (Ensembl)
GlycolysisPathwayWP534 (WikiPathways)
HIF1AGeneProductENSG00000100644 (Ensembl)
IronMetaboliteHMDB15531 (HMDB)
KEAP1GeneProductENSG00000079999 (Ensembl)
L-malateMetaboliteCHEBI:15589 (ChEBI)
LDHAGeneProductENSG00000134333 (Ensembl)
NFE2L2GeneProductENSG00000116044 (Ensembl)
NRF2/ARE PathwayPathway
O2+MetaboliteCHEBI:29371 (ChEBI)
OxaloacetateMetaboliteCHEBI:30744 (ChEBI)
PDHA1GeneProductENSG00000131828 (Ensembl)
PDHA2GeneProductENSG00000163114 (Ensembl)
PDHBGeneProductENSG00000168291 (Ensembl)
PDK1GeneProductENSG00000152256 (Ensembl)
PRKAA1GeneProductENSG00000132356 (Ensembl)
PRKAB1GeneProductENSG00000111725 (Ensembl)
PRKAG1GeneProductENSG00000181929 (Ensembl)
RPS6GeneProductENSG00000137154 (Ensembl)
SLC11A2GeneProductENSG00000110911 (Ensembl)
Succinyl-CoAMetaboliteHMDB01022 (HMDB)
TP53GeneProductENSG00000141510 (Ensembl)
VEGFAGeneProductENSG00000112715 (Ensembl)
alpha-ketoglutarateMetaboliteCHEBI:16810 (ChEBI)
citrateMetaboliteCHEBI:16947 (ChEBI)
fatty acidsMetaboliteCHEBI:35366 (ChEBI)
fumarateMetaboliteCHEBI:29806 (ChEBI)
glucoseMetaboliteCHEBI:17234 (ChEBI)
glutamateMetaboliteCHEBI:14321 (ChEBI)
ironMetaboliteCHEBI:18248 (ChEBI)
isocitrateMetaboliteCHEBI:16087 (ChEBI)
lactateMetaboliteCHEBI:24996 (ChEBI)
malonyl-CoAMetaboliteCHEBI:57384 (ChEBI)
phospholipidsMetaboliteCHEBI:16247 (ChEBI)
pyruvateMetaboliteCHEBI:15361 (ChEBI)
succinateMetaboliteCHEBI:30031 (ChEBI)

Annotated Interactions

No annotated interactions

Personal tools